Compare TMCI & KINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMCI | KINS |
|---|---|---|
| Founded | 2014 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.0M | 279.5M |
| IPO Year | 2021 | 2013 |
| Metric | TMCI | KINS |
|---|---|---|
| Price | $5.19 | $22.93 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.17 | N/A |
| AVG Volume (30 Days) | ★ 298.9K | 93.7K |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 1.03% |
| EPS Growth | N/A | ★ 94.59 |
| EPS | N/A | ★ 1.86 |
| Revenue | $212,690,000.00 | ★ $214,867,301.00 |
| Revenue This Year | N/A | $18.83 |
| Revenue Next Year | $6.15 | $15.85 |
| P/E Ratio | ★ N/A | $12.49 |
| Revenue Growth | 1.59 | ★ 38.50 |
| 52 Week Low | $1.17 | $13.83 |
| 52 Week High | $5.44 | $23.42 |
| Indicator | TMCI | KINS |
|---|---|---|
| Relative Strength Index (RSI) | 61.43 | 67.82 |
| Support Level | $3.96 | $18.35 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.50 | 0.86 |
| MACD | 0.10 | 0.33 |
| Stochastic Oscillator | 87.62 | 86.05 |
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.